Regeneron Pharmaceuticals and TriNetX have announced a major strategic collaboration aimed at advancing drug discovery and delivering next-generation digital health solutions.
As part of the deal, Regeneron will invest up to $200 million in TriNetX, solidifying what executives describe as a transformative partnership at the intersection of genomics, real-world health data, and AI-driven innovation.
The partnership gives Regeneron exclusive access to TriNetX’s massive network of phenotypic data—covering approximately 300 million de-identified and anonymized patients—paired with Regeneron’s genomic and proteomic capabilities.
This collaboration will expand Regeneron’s already world-leading genomic and proteomic Electronic Health Record (EHR)-linked database, a cornerstone of its therapeutics pipeline.
TriNetX will provide Regeneron secure, licensed access to de-identified health data from its global network of health system partners, including 170 million individuals in the United States. Regeneron will then match portions of this data with genomic and proteomic information generated by the Regeneron Genetics Center (RGC), all in compliance with HIPAA and GDPR privacy standards.
The RGC has spent over a decade building high-throughput, cost-efficient DNA sequencing and proteomics platforms, collaborating with more than 150 global life sciences and healthcare partners. The new TriNetX collaboration will further expand this dataset, fueling AI-driven drug discovery and enabling digital health innovations.
“We are delighted to work with Regeneron, and specifically the Regeneron Genetics Center team, to advance human health through the application of intelligence-driven information technology, powered by our trusted data,” said Jeff Margolis, TriNetX Executive Chairman.
“Our team is gratified to be selected by Regeneron to provide access to TriNetX’s unique breadth and depth of research-ready data, across our extensive federated global network of academic medical centers and other leading healthcare research sites.”
"This is a major milestone for the RGC and a powerful new pathway to achieve our core mission: building the world's largest and richest human health database to drive drug development and pioneer digital health solutions for consumers, patients and providers," said Aris Baras, Senior Vice President, Head of RGC and Co-head of Regeneron Genetic Medicines.
"TriNetX has built a world-leading platform with a proven track record of enabling research at scale. The RGC has spent over a decade generating genomic and now proteomic data and integrating these molecular data with longitudinal health records at large-scale.
"Combining these platforms brings together powerful human health databases with analytical and AI capabilities to help discover and develop innovative medicines for devastating diseases and create digital health solutions that we hope will transform our ability to predict, prevent and manage disease."
"We are looking forward to working with the TriNetX team," added Andrew Deubler, Senior Vice President, RGC Chief Business and Administrative Officer.
"Our RGC strategic investments catalyze innovation, driving advancements in cutting-edge technologies that accelerate drug discovery and development, as well as help us develop innovative digital health solutions. This deal represents the latest and one of our most significant collaborations, and we look forward to continuing to expand our network of top-tier partners as we pursue our mission."
